Soumit Roy
Stock Analyst at Edward Jones
(2.89)
# 1,754
Out of 5,055 analysts
44
Total ratings
30.3%
Success rate
5.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Soumit Roy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVAX Evaxion | Initiates: Buy | $10 | $5.21 | +91.94% | 1 | Oct 30, 2025 | |
| AVXL Anavex Life Sciences | Downgrades: Hold | n/a | $3.58 | - | 1 | Oct 24, 2025 | |
| CGON CG Oncology | Initiates: Buy | $50 | $41.25 | +21.21% | 1 | Sep 8, 2025 | |
| TARA Protara Therapeutics | Initiates: Buy | $21 | $5.57 | +277.02% | 1 | May 22, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $40 | $20.69 | +93.33% | 1 | May 20, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Buy | $36 → $27 | $21.76 | +24.08% | 2 | May 16, 2025 | |
| ACRV Acrivon Therapeutics | Downgrades: Hold | n/a | $2.38 | - | 2 | May 16, 2025 | |
| ONCY Oncolytics Biotech | Downgrades: Hold | n/a | $1.05 | - | 2 | May 16, 2025 | |
| MURA Mural Oncology | Downgrades: Hold | n/a | $2.08 | - | 2 | Mar 25, 2025 | |
| CRVO CervoMed | Upgrades: Buy | $15 | $8.21 | +82.70% | 3 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.67 | +114.13% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $34 | $22.02 | +54.41% | 2 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $1.59 | +2,164.15% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $3.16 | +912.66% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $8.72 | +3.21% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $12.06 | +40.96% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.58 | +403.88% | 1 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $4 | $0.59 | +574.08% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.78 | - | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.51 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $26 | $8.77 | +196.47% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $28.72 | +143.73% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $76.43 | -86.92% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.41 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $15.15 | +428.05% | 1 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.52 | - | 2 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $3.06 | +10,357.52% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $810 | $5.14 | +15,658.75% | 1 | Feb 24, 2021 |
Evaxion
Oct 30, 2025
Initiates: Buy
Price Target: $10
Current: $5.21
Upside: +91.94%
Anavex Life Sciences
Oct 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $3.58
Upside: -
CG Oncology
Sep 8, 2025
Initiates: Buy
Price Target: $50
Current: $41.25
Upside: +21.21%
Protara Therapeutics
May 22, 2025
Initiates: Buy
Price Target: $21
Current: $5.57
Upside: +277.02%
ArriVent BioPharma
May 20, 2025
Initiates: Buy
Price Target: $40
Current: $20.69
Upside: +93.33%
Enliven Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $36 → $27
Current: $21.76
Upside: +24.08%
Acrivon Therapeutics
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.38
Upside: -
Oncolytics Biotech
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.05
Upside: -
Mural Oncology
Mar 25, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.08
Upside: -
CervoMed
Mar 13, 2025
Upgrades: Buy
Price Target: $15
Current: $8.21
Upside: +82.70%
Mar 12, 2025
Initiates: Buy
Price Target: $10
Current: $4.67
Upside: +114.13%
Mar 10, 2025
Upgrades: Buy
Price Target: $34
Current: $22.02
Upside: +54.41%
Feb 11, 2025
Upgrades: Buy
Price Target: $36
Current: $1.59
Upside: +2,164.15%
Jan 28, 2025
Initiates: Buy
Price Target: $32
Current: $3.16
Upside: +912.66%
Oct 31, 2024
Initiates: Buy
Price Target: $9
Current: $8.72
Upside: +3.21%
Oct 31, 2024
Initiates: Buy
Price Target: $17
Current: $12.06
Upside: +40.96%
Sep 17, 2024
Initiates: Buy
Price Target: $13
Current: $2.58
Upside: +403.88%
Sep 11, 2024
Maintains: Buy
Price Target: $6 → $4
Current: $0.59
Upside: +574.08%
Jul 1, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.78
Upside: -
May 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.51
Upside: -
Apr 17, 2024
Maintains: Buy
Price Target: $22 → $26
Current: $8.77
Upside: +196.47%
Apr 16, 2024
Initiates: Buy
Price Target: $70
Current: $28.72
Upside: +143.73%
Apr 11, 2024
Upgrades: Buy
Price Target: $10
Current: $76.43
Upside: -86.92%
May 23, 2023
Downgrades: Hold
Price Target: n/a
Current: $5.41
Upside: -
Apr 19, 2023
Initiates: Buy
Price Target: $80
Current: $15.15
Upside: +428.05%
Nov 16, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.52
Upside: -
Nov 8, 2022
Initiates: Buy
Price Target: $320
Current: $3.06
Upside: +10,357.52%
Feb 24, 2021
Initiates: Buy
Price Target: $810
Current: $5.14
Upside: +15,658.75%